ritanserin has been researched along with Hypertension in 11 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have studied the acute effects of the serotonergic type-2 (5-HT2) antagonists ketanserin and ritanserin given as single oral doses to patients with essential hypertension." | 9.06 | Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. ( Ball, SG; Hosie, J; Robertson, JI; Stott, DJ, 1987) |
| "We have given the selective 5 HT2 antagonist ritanserin in a dose of 10 mg twice daily for 4 weeks in a double-blind, randomized, placebo-controlled, parallel group study of 18 patients with untreated essential hypertension." | 9.06 | The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. ( Ball, SG; Hosie, J; Lowe, GD; Saniabadi, AR; Stott, DJ, 1988) |
| "We have studied the acute effects of the serotonergic type-2 (5-HT2) antagonists ketanserin and ritanserin given as single oral doses to patients with essential hypertension." | 5.06 | Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. ( Ball, SG; Hosie, J; Robertson, JI; Stott, DJ, 1987) |
| "In patients with essential hypertension, ketanserin (40 mg once or twice daily) reduces the blood pressure in mono- and combination therapy." | 5.06 | Experience with ketanserin and ritanserin in hypertensive patients. ( Hedner, T; Persson, B, 1988) |
| "We have given the selective 5 HT2 antagonist ritanserin in a dose of 10 mg twice daily for 4 weeks in a double-blind, randomized, placebo-controlled, parallel group study of 18 patients with untreated essential hypertension." | 5.06 | The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. ( Ball, SG; Hosie, J; Lowe, GD; Saniabadi, AR; Stott, DJ, 1988) |
| " Whereas the blood pressure reduction to acute administration of ketanserin was directly related to its ability to shift the dose-response curve of phenylephrine (alpha 1-adrenergic blockade), the same relationship was not apparent following chronic treatment with ketanserin." | 1.27 | Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat. ( Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1988) |
| "Ketanserin is a new antihypertensive agent with affinity to serotonin (5-HT)2 receptors and at higher concentrations also to alpha 1-adrenoceptors." | 1.27 | Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat. ( Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, RJ | 1 |
| Wright, KF | 1 |
| Allen, AD | 1 |
| Taylor, DR | 1 |
| Hosie, J | 2 |
| Stott, DJ | 2 |
| Robertson, JI | 1 |
| Ball, SG | 2 |
| Persson, B | 5 |
| Gradin, K | 3 |
| Pettersson, A | 4 |
| Hedner, T | 5 |
| Chau, NP | 1 |
| Pithois-Merli, I | 1 |
| Levenson, J | 1 |
| Simon, AC | 1 |
| Nelson, M | 1 |
| Coghlan, JP | 1 |
| Denton, DA | 1 |
| Tresham, JJ | 1 |
| Whitworth, JA | 1 |
| Scoggins, BA | 1 |
| Saniabadi, AR | 1 |
| Lowe, GD | 1 |
| Smits, J | 1 |
| van Dorsten, F | 1 |
| Struyker Boudier, H | 1 |
5 trials available for ritanserin and Hypertension
| Article | Year |
|---|---|
Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Topics: Adult; Affect; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Ketanserin; Male; Mid | 1987 |
Experience with ketanserin and ritanserin in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1988 |
Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.
Topics: Arm; Blood Pressure; Brachial Artery; Double-Blind Method; Hand; Humans; Hypertension; Ketanserin; M | 1989 |
Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Histamine H2 Antagonists; Humans; Hyper | 1987 |
The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
Topics: Aged; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Forearm; Heart Rate; Humans; | 1988 |
6 other studies available for ritanserin and Hypertension
| Article | Year |
|---|---|
Cardiovascular and renal actions of AHR-16303B, an antagonist of 5-HT2 receptors and calcium channels, in hypertensive and normotensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular System; Dose | 1991 |
Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Male; Phenyl | 1988 |
Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Decerebrate State; Dose-Response Relationship, Drug; Electric Stimulation; | 1985 |
Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Hypertension; Ketan | 1985 |
Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
Topics: Animals; Blood Pressure; Cardiac Output; Heart Rate; Hypertension; Ketanserin; Phenylephrine; Piperi | 1987 |
Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Heart Rate; Hypertension; Ketanserin; Male; Piperidines; Prazosin; Pressore | 1988 |